Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe Y, Andreeff M.
Yamatani K, et al. Among authors: hori a.
Transl Oncol. 2022 Apr;18:101354. doi: 10.1016/j.tranon.2022.101354. Epub 2022 Feb 1.
Transl Oncol. 2022.
PMID: 35114569
Free PMC article.